ClinicalTrials.gg
CompletedNCT04268303SERENITY IUpdated Aug 11, 2026Results posted

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

A Phase 3 interventional study of Sublingual film containing dexmedetomidine (BXCL501) and Placebo Film in Agitation, Schizophrenia and Schizo Affective Disorder, sponsored by BioXcel Therapeutics Inc. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Primary conditionSchizophreniaRegistry: Psychomotor AgitationReclassifiedWhy we changed it
Registry
Psychomotor Agitation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Schizophrenia
Why
  1. The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Schizophrenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
149th of 1,319
380 · median 66
Started
2020
with 43 others
Phase 3
196 of 1,465
19 open now
Registered
1,164th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 149th largest by enrollment of the 1,319 interventional ones that give a count, is one of 44 that started in 2020, is one of 196 in phase 3, and was the 1,164th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.

Read the detailed description

The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg, 120µg BXCL501, or placebo. Male and female adults with acute agitation associated with schizophrenia, schizoaffective disorder, or schizophreniform disorder will be enrolled. Eligible subjects may be identified in outpatient clinics, mental health, psychiatric or medical emergency services including medical/psychiatric observation units, or as newly admitted to a hospital setting for acute agitation or already in hospital for chronic underlying conditions. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing.

03

Conditions studied

  • Agitation
  • Schizophrenia
  • Schizo Affective Disorder
  • Schizoaffective Disorder
  • Schizophreniform Disorders

Browse trials for

04

In context

Schizophrenia Reclassified

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

This study's enrollment of 380 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.

Compared within Schizophrenia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for inclusion in the study if he or she meets the following criteria:

  1. Male and female patients between the ages of 18 to 75 years, inclusive.
  2. Patients who have met criteria for schizophrenia, schizoaffective, or schizophreniform disorder.
  3. Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).
  4. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.
  5. Patients who read, understand, and provide written .
  6. Patients who are in good general health prior to study participation as determined by a detailed medical history, physical examination, 12-lead with rhythm strip, blood chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator.
  7. Participants who agree to use a medically acceptable and effective method

Exclusion criteria

Exclusion Criteria:

A subject will be excluded from the study if he or she meets the following criteria:

  1. Patients with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse (with the exception of THC) during urine screening.
  2. Use of benzodiazepines, hypnotics and anti-psychotic drugs in the 4 hours before study treatment.
  3. Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin) or other prohibited medications.
  4. Patients who are judged to be at significant risk of suicide
  5. Female patients who have a positive pregnancy test at screening or are breastfeeding.
  6. Patients who have hydrocephalus, seizure disorder, or history of significant head trauma, stroke, , subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease or focal neurological findings.
  7. History of syncope or other syncopal attacks, current evidence of hypovolemia, orthostatic hypotension.
  8. Patients with laboratory or abnormalities considered by the investigator.
  9. Patients with serious or unstable medical illnesses.
  10. Patients who have received an drug within 30 days prior to the current agitation episode.
  11. Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving DEX.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    120 Micrograms

    Sublingual film containing 120 Micrograms dexmedetomidine

    Drug: Sublingual film containing dexmedetomidine (BXCL501)

  • Experimental
    180 Micrograms

    Sublingual film containing 180 Micrograms dexmedetomidine

    Drug: Sublingual film containing dexmedetomidine (BXCL501)

  • Placebo comparator
    Placebo

    Sublingual placebo film

    Drug: Placebo Film

Interventions

07

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score

    The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

    Time frame: Baseline and 2 hours

Secondary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time

    Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

    Time frame: Baseline and 10, 20, 30, 45, 60, 90 minutes post-dose

08

Results

Posted Jun 18, 2023

Participant flow

Participant flow — Overall Study
Milestone120 Micrograms180 MicrogramsPlacebo
Started129125126
Completed126123123
Not completed323
Withdrew: Lost to follow-up112
Withdrew: Withdrawal by subject011
Withdrew: Adverse event200

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score

The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

Time frame:
Baseline and 2 hours
Reported as:
Mean · score on a scale
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
score on a scale120 Micrograms180 MicrogramsPlacebo
Baseline17.5 ± 2.4617.6 ± 2.6917.6 ± 2.26
2 Hours-8.4 ± 4.83-10.4 ± 4.34-4.7 ± 4.69
Statistical analysis
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time

Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

Time frame:
Baseline and 10, 20, 30, 45, 60, 90 minutes post-dose
Reported as:
Mean · score on a scale
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time
score on a scale120 Micrograms180 MicrogramsPlacebo
Baseline17.5 ± 2.4617.6 ± 2.6917.6 ± 2.26
10 minutes-1.3 ± 2.50-2.0 ± 3.19-1.3 ± 2.17
20 minutes-2.8 ± 4.03-3.9 ± 4.54-2.5 ± 3.20
30 minutes-4.4 ± 4.90-5.7 ± 5.27-3.1 ± 3.56
45 minutes-5.7 ± 5.18-7.6 ± 5.32-3.6 ± 3.78
60 minutes-6.9 ± 5.06-8.8 ± 4.96-4.1 ± 4.16
90 minutes-8.0 ± 5.00-9.8 ± 4.60-4.6 ± 4.38
Statistical analysis
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = <0.0001
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = 0.0075
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = 0.0032
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = 0.4097
  • 180 Micrograms vs Placebo · Mixed Models Analysis · p = 0.0457
  • 120 Micrograms vs Placebo · Mixed Models Analysis · p = 0.9720

Adverse events

Collected over 30 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
120 Micrograms0/129 (0%)0/129 (0%)51/129 (39.5%)
180 Micrograms0/126 (0%)0/126 (0%)47/126 (37.3%)
Placebo0/126 (0%)0/126 (0%)19/126 (15.1%)
Most frequent other events
Most frequent other events
Event120 Micrograms180 MicrogramsPlacebo
SomnolenceNervous system disorders28/12929/12610/126
Dry mouthGastrointestinal disorders10/1295/1262/126
DizzinessNervous system disorders3/1298/1261/126
HypotensionVascular disorders8/1295/1260/126
Hypoesthesia oralNervous system disorders5/1297/1260/126
Orthostatic hypotensionVascular disorders2/1297/1260/126
HeadacheNervous system disorders6/1294/1266/126
Paresthesia oralNervous system disorders5/1293/1261/126

Baseline characteristics

Safety population (all participants who received study drug). One participant enrolled and randomized to the 120 μg group was enrolled a second time at a different site and randomized to the 180 μg group. The data from the first enrollment and treatment (120 μg) were included in the efficacy analyses. The data from both enrollments (120 μg and 180 μg) were included in the safety analyses and counted separately for each treatment group.

Age, Continuous
Age, Continuous(years)120 Micrograms180 MicrogramsPlaceboTotal
Mean45.7 ± 11.346.0 ± 11.945.1 ± 11.145.6 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)120 Micrograms180 MicrogramsPlaceboTotal
Female524344139
Male778282241
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)120 Micrograms180 MicrogramsPlaceboTotal
Hispanic or Latino1713737
Not Hispanic or Latino112112119343
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)120 Micrograms180 MicrogramsPlaceboTotal
Black or African American92102102296
White33212175
Other4239
Hispanic or Latino1713737
Positive and Negative Syndrome Scale-Excited Component
Positive and Negative Syndrome Scale-Excited Component(units on a scale)120 Micrograms180 MicrogramsPlaceboTotal
Mean17.5 ± 2.517.6 ± 2.717.6 ± 2.317.6 ± 2.5
09

Study locations

15 sites
  • BioXcel Clinical Research Site
    Little Rock, Arkansas 72211, United States
  • BioXcel Clinical Research Site
    Cerritos, California 78754, United States
  • BioXcel Clinical Research Site
    Culver City, California 90230, United States
  • BioXcel Clinical Research Site
    Long Beach, California 90806, United States
  • BioXcel Clinical Research Site
    Orange, California 92868, United States
  • BioXcel Clinical Research Site
    Miami Lakes, Florida 33016, United States
  • BioXcel Clinical Research Site
    Chicago, Illinois 60640, United States
  • BioXcel Clinical Research Site
    Gaithersburg, Maryland 20877, United States
  • BioXcel Clinical Research Site
    Las Vegas, Nevada 89102, United States
  • BioXcel Clinical Research Site
    Berlin, New Jersey 08009, United States
  • BioXcel Clinical Research Site
    Marlton, New Jersey 08053, United States
  • BioXcel Clinical Research Site
    Charleston, South Carolina 29407, United States
  • BioXcel Clinical Research Site
    Austin, Texas 78754, United States
  • BioXcel Clinical Research Site
    DeSoto, Texas 75115, United States
  • BioXcel Clinical Research Site
    Richardson, Texas 75080, United States
10

References and documents

Publications

  • Citrome L, Preskorn SH, Lauriello J, Krystal JH, Kakar R, Finman J, De Vivo M, Yocca FD, Risinger R, Rajachandran L. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial. J Clin Psychiatry. 2022 Oct 3;83(6):22m14447. doi: 10.4088/JCP.22m14447. PubMed 36198061 ↗
  • Citrome L, Risinger R, Rajachandran L, Robison H. Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed. Adv Ther. 2022 Oct;39(10):4821-4835. doi: 10.1007/s12325-022-02274-3. Epub 2022 Aug 24. PubMed 36002761 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in May 2020, 3 months.

Results were first posted in Jun 2023, 3 years 1 month after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 3 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2020
First posted
Feb 13, 2020
StartActual
Jan 24, 2020
Primary completionActual
May 6, 2020
CompletionActual
May 6, 2020
Results first posted
Jun 18, 2023
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04268303
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Feb 13, 2020
Start date
Jan 24, 2020
Primary completion
May 6, 2020
Completion
May 6, 2020
Results posted
Jun 18, 2023
Last update
Aug 11, 2026

Study contacts

BioXcel MM, MD
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion